The Dual Vitamin D Pathways: Considerations for Adequate Supplementation

The Dual Vitamin D Pathways: Considerations for Adequate Supplementation

Identification: nnj_jf10A1
Issue: January-February 2010
Volume: Vol. 37, No. 1
Credits (Post Test and/or Evaluation Required)
Available until 02/29/2012
  • 1.40 - CH
  • 80.00 - Rx


This article is available to members for free.

Goal: To provide an overview of the treatment of vitamin D deficiency and insufficiency in patients with CKD with vitamin D supplementation via the endocrine and autocrine pathways.


  1. Discuss the physiologic and molecular functions of vitamin D.
  2. Describe the pathogenesis of secondary hyperparathyroidism.
  3. Discuss non-kidney related outcomes that result from lack of adequate therapy.
  4. Understand the rationale for dual therapies in Stage 5 chronic kidney disease.

Statement of Disclosure: The author has disclosed that she is an employee of Cytochroma, Inc., a clinical stage specialty pharmaceutical company developing vitamin D products for commercialization.

Acknowledgment: The author would like to acknowledge Robert P. Heaney, MD, for his article "Vitamin D in Health and Disease," which served as a primary resource in the development of this article.


Credits Available

Expired On: Feb 29, 2012

You must be logged in and own this product in order to post comments.